genedrive plc

Corporate Governance

AIM Rule 26

Reports, presentations & documents

Advisers

Shareholder Information

Team

Analyst notes

Investors

Why Invest

Media

Announcements

Blog

Home

Montserrat

Finalresultspresentation30June2024_bngf2o.pdf

Genedrive’s leadership team outlined a year of significant regulatory, clinical, and commercial progress as the company moves closer to widespread clinical adoption of its rapid pharmacogenetic testing platform.

Major regulatory milestones – NICE recommendation for CYP2C19 ID Kit and U.S. FDA breakthrough designation for MT-RNR1 Kit.

Commercial readiness – Manufacturing and distribution infrastructure in place to scale across NHS and international markets.

Strong clinical validation – Expanding real-world evidence base supporting Genedrive’s technology in stroke and neonatal care.

Strategic focus – Near-term goal of driving NHS adoption and building strategic partnerships to extend into global markets.

Investors are invited to explore the presentation and submit questions to the management team directly via the hub.

Final Results Presentation - 30 June 2024